Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M254,207Revenue $M49,242Net Margin (%)23.2Z-Score5.1
Enterprise Value $M261,325EPS $1.7Operating Margin %34.3F-Score7
P/E(ttm))22.0Cash Flow Per Share $0Pre-tax Margin (%)31.0Higher ROA y-yY
Price/Book11.510-y EBITDA Growth Rate %4.7Quick Ratio1.5Cash flow > EarningsY
Price/Sales5.35-y EBITDA Growth Rate %4.9Current Ratio1.9Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %-2.9ROA % (ttm)17.6Higher Current Ratio y-yY
Dividend Yield %3.0Insider Buy (3m)0ROE % (ttm)56.8Less Shares Outstanding y-yN
Payout Ratio %63.0Shares Outstanding M6,795ROI % (ttm)33.6Gross Margin Increase y-yY

Gurus Latest Trades with RHHBY

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
RHHBYKen Fisher 2014-06-30 Reduce-0.07%$35.42 - $38.07
($36.82)
$ 37.412%Reduce -49.71%1,813,443
RHHBYKen Fisher 2014-03-31 Add0.07%$18.14 - $38.17
($29.75)
$ 37.4126%Add 99%1,803,070
RHHBYTweedy Browne 2013-06-30 Sold Out $28.92 - $32.98
($30.92)
$ 37.4121%Sold Out0
RHHBYKen Fisher 2013-03-31 Add0.12%$25.25 - $29.3
($27.74)
$ 37.4135%Add 634.57%897,861
RHHBYTweedy Browne 2012-09-30 Reduce-0.03%$20.95 - $24.07
($22.41)
$ 37.4167%Reduce -24.31%62,164
RHHBYVanguard Health Care Fund 2012-06-30 Add2.96%$19.47 - $23.14
($21.16)
$ 37.4177%Add 543.36%4,273,977
RHHBYKen Fisher 2012-06-30 Reduce-0.01%$19.47 - $23.14
($21.16)
$ 37.4177%Reduce -24.26%154,713
RHHBYKen Fisher 2012-03-31 Reduce-1.27%$21.55 - $22.17
($20.04)
$ 37.4187%Reduce -98.02%204,276
RHHBYTweedy Browne 2012-03-31 Reduce-0.04%$21.55 - $22.17
($20.04)
$ 37.4187%Reduce -22.19%82,130
RHHBYKen Fisher 2009-03-31 Add1.01%$13.37 - $18.53
($15.95)
$ 37.41134%Add 96.11%12,225,393
RHHBYVanguard Health Care Fund 2009-03-31 Reduce-0.2%$13.37 - $18.53
($15.95)
$ 37.41134%Reduce -52.1%429,320
RHHBYVanguard Health Care Fund 2008-12-31 Add2.01%$31.33 - $38.5
($35.55)
$ 37.415%Add 95.76%5,113,297
RHHBYPRIMECAP Management 2008-12-31 Sold Out -1.2%$31.33 - $38.5
($35.55)
$ 37.415%Sold Out0
RHHBYKen Fisher 2008-12-31 Reduce-1.15%$8.06 - $19.92
($17.52)
$ 37.41114%Reduce -56.79%6,233,841
RHHBYPRIMECAP Management 2008-09-30 Buy 1.2%$20.05 - $22.89
($21.5)
$ 37.4174%New holding, 4306500 sh.4,306,500
RHHBYKen Fisher 2008-06-30 Add1.14%$19.95 - $23.69
($21.4)
$ 37.4175%Add 223.59%7,046,449
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

RHHBY is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
RHHBY Ken Fisher 2014-09-301,891,4060.030.15+4.3%
Premium Most recent portfolio changes are included for Premium Members only!


RHHBY: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about RHHBY :

    Quarterly/Annual Reports about RHHBY:

      News about RHHBY:

      Articles On GuruFocus.com
      The Top 5 European Stocks Held During Q3 Nov 25 2014 
      Tweedy Browne Global Reports its Top Five Picks of Q3 Oct 21 2014 
      Widely Held Guru Stocks Trading In Europe Sep 22 2014 
      Dodge & Cox Second Quarter 2014 Commentary Jul 23 2014 
      Tweedy Browne Global Reports Their Second Quarter Portfolio Jul 18 2014 
      Signature Select Canadian Fund's Top Holdings Jul 02 2014 
      The Tweedy Browne Global Value Fund's Top First Quarter Holdings Apr 22 2014 
      Most Popular International Stocks of Investment Gurus Mar 05 2014 
      John Rogers' Ariel Fund Comments on Roche Feb 28 2014 
      Ariel International Fund & Ariel Global Fund - Healthy Ideas Feb 28 2014 


      More From Other Websites
      Immunomedics' Veltuzumab Receives Orphan Drug Status Nov 24 2014
      AstraZeneca Targets More than $45B in Revenues in 2023 Nov 19 2014
      Inovio-Roche End Deal for Development of Cancer Therapy Nov 18 2014
      Celldex Therapeutics Surges on Positive Rindopepimut Data Nov 18 2014
      Roche's (RHHBY) Avastin Label Expansion Approved by FDA Nov 18 2014
      Puma Biotechnology Falls on Disappointing Neratinib Data Nov 17 2014
      Celldex Immunotherapy Prolongs Survival for Recurrent Brain Tumor Patients Nov 14 2014
      FDA Approves Genentech’s Avastin (bevacizumab) Plus Chemotherapy to Treat Women with... Nov 14 2014
      Cleveland Biolabs; A Diverse Play on Both Biodefense and Cancer Nov 13 2014
      Roche Teams Up with LabCentral to Support Biotech Startups Nov 12 2014
      Oxigene Faces Challenges for Ovarian Cancer Drug Even With Encouraging Data Nov 12 2014
      PDL BioPharma's Q3 Earnings and Revenues Increase Y/Y Nov 11 2014
      Dr. Reddy's Laboratories: The Bridge to 2016 Nov 10 2014
      Will Inovio (INO) Disappoint Expectations for Q3 Earnings? Nov 07 2014
      FDA revokes Ranbaxy’s right to generic versions of Nexium, Valcyte Nov 06 2014
      [$$] FDA Says Ranbaxy Can't Make Generic Versions of Nexium, Valcyte Nov 06 2014
      Regeneron Q3 Earnings Miss As U.S. Eylea Sales Falter Nov 04 2014
      Will Exelixis (EXEL) Disappoint This Earnings Season? Nov 03 2014
      Will Teva (TEVA) Beat Q3 Earnings on Strong Generic Sales? Oct 29 2014
      Ventana announces collaboration to develop companion diagnostics for ImmunoGen's targeted anticancer... Oct 28 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      Steve.dunfield@google
      ReplySteve.dunfield@google - 7 months ago
      Adjust for split?
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK